Disease targets of OncoTartis drugs include several categories of cancer such as hematological malignancies, gender tissues-associated malignancies such as prostate, breast and ovarian cancers, as well as melanoma. Altogether, TARTIS approach targets 43% of all newly diagnosed cancers and responsible for 25% of all cancer-related deaths in the US in 2010. Sadly, no cardinal treatment improvement in these malignancies has been achieved during last 20 years.